Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27496993 | 0.82 | CYP11B1 (0.49) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL4003305 | 0.79 | CYP11B1 (0.44) | CYP11B2CYP11B1CYP19A1PKM | |
| SCHEMBL1698952 | 0.79 | CYP11B1 (0.39) | CYP11B2CYP11B1 | |
| SCHEMBL4833974 | 0.79 | CYP11B1 (0.44) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL2359179 | 0.79 | NOS1 (0.52) | CYP11B2CYP11B1NOTUM | |
| SCHEMBL14243162 | 0.77 | CYP11B1 (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL3630524 | 0.76 | CYP11B1 (1.00) | CYP11B2CYP11B1CYP19A1 | |
| SCHEMBL16187816 | 0.74 | CYP11B1 (0.39) | CYP11B2CYP11B1CYP19A1PKM | |
| SCHEMBL16099328 | 0.73 | IDO1 (0.39) | CYP11B2CYP11B1CYP19A1PKM | |
| SCHEMBL16099490 | 0.72 | HSD11B1 (0.59) | CYP11B2CYP11B1NOTUMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3363434-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970131-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CYP11B2 244/4885CYP11B1 201/4885NOTUM 572/4885 |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CYP11B2 244/4885CYP11B1 201/4885NOTUM 572/4885 |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CYP11B2 244/4885CYP11B1 201/4885NOTUM 572/4885 |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CYP11B2 244/4885CYP11B1 201/4885NOTUM 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.